Details of the Drug

General Information of Drug (ID: DMM2LTC)

Drug Name

KSI-301

Indication

Disease Entry	ICD 11	Status	REF
Diabetic macular edema	9B71.02	Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

Antibody biopolymer conjugate

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Vascular endothelial growth factor (VEGF)	TT9HKJA	VEGFA_HUMAN ; VEGFB_HUMAN ; VEGFC_HUMAN ; VEGFD_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04603937) A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) (GLIMMER). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Kodiak Sciences.